Patents Assigned to rPeptide LLC
  • Anti-amyloid-beta antibodies
    Patent number: 11161898
    Abstract: The present invention relates, in part, to isolated antibodies that specifically interact with and show measurable binding affinity to an epitope of the amyloid-beta (A?) protein. Such antibodies may be used for the modulation of A? activity and/or aggregation or amyloidosis, to study the effects of the A? protein on cell function and, in certain embodiments, for the treatment and/or prevention of a disease or condition associated with A? activity, aggregation, and/or amyloidosis.
    Type: Grant
    Filed: November 8, 2019
    Date of Patent: November 2, 2021
    Assignee: rPeptide LLC
    Inventors: Quentin Florence, Nanda Menon, William Moffitt, Bill Lunsford, III
  • Anti-tau antibodies
    Patent number: 10696739
    Abstract: The present invention relates, in part, to isolated antibodies that specifically interact with and show measurable binding affinity to an epitope of the tau protein. Such antibodies may be used for the modulation of tau activity and/or aggregation, to study the effects of the tau protein on cell function and, in certain embodiments, for the treatment and/or prevention of a disease or condition associated with neurodegenerative tauopathy.
    Type: Grant
    Filed: January 17, 2019
    Date of Patent: June 30, 2020
    Assignee: rPeptide, LLC
    Inventors: Quentin Florence, Nanda Menon, William Moffitt, Bill Lunsford, III
  • Anti-amyloid-beta antibodies
    Patent number: 10494425
    Abstract: The present invention relates, in part, to isolated antibodies that specifically interact with and show measurable binding affinity to an epitope of the amyloid-beta (A?) protein. Such antibodies may be used for the modulation of A? activity and/or aggregation or amyloidosis, to study the effects of the A? protein on cell function and, in certain embodiments, for the treatment and/or prevention of a disease or condition associated with A? activity, aggregation, and/or amyloidosis.
    Type: Grant
    Filed: February 23, 2016
    Date of Patent: December 3, 2019
    Assignee: rPeptide, LLC
    Inventors: Quentin Florence, Nanda Menon, William Moffitt, Bill Lunsford, III
  • ANTI-TAU ANTIBODIES
    Publication number: 20190211086
    Abstract: The present invention relates, in part, to isolated antibodies that specifically interact with and show measurable binding affinity to an epitope of the tau protein. Such antibodies may be used for the modulation of tau activity and/or aggregation, to study the effects of the tau protein on cell function and, in certain embodiments, for the treatment and/or prevention of a disease or condition associated with neurodegenerative tauopathy.
    Type: Application
    Filed: January 17, 2019
    Publication date: July 11, 2019
    Applicant: rPeptide LLC
    Inventors: Quentin Florence, Nanda Menon, William Moffitt, Bill Lunsford, III
  • Anti-tau antibodies
    Patent number: 10202444
    Abstract: The present invention relates, in part, to isolated antibodies that specifically interact with and show measurable binding affinity to an epitope of the tau protein. Such antibodies may be used for the modulation of tau activity and/or aggregation, to study the effects of the tau protein on cell function and, in certain embodiments, for the treatment and/or prevention of a disease or condition associated with neurodegenerative tauopathy.
    Type: Grant
    Filed: February 23, 2016
    Date of Patent: February 12, 2019
    Assignee: rPeptide, LLC
    Inventors: Quentin Florence, Nanda Menon, William Moffitt, Bill Lunsford, III
  • ANTI-TAU ANTIBODIES
    Publication number: 20180051073
    Abstract: The present invention relates, in part, to isolated antibodies that specifically interact with and show measurable binding affinity to an epitope of the tau protein. Such antibodies may be used for the modulation of tau activity and/or aggregation, to study the effects of the tau protein on cell function and, in certain embodiments, for the treatment and/or prevention of a disease or condition associated with neurodegenerative tauopathy.
    Type: Application
    Filed: February 23, 2016
    Publication date: February 22, 2018
    Applicant: rPeptide LLC
    Inventors: Quentin FLORENCE, Nanda MENON, William MOFFITT, Bill LUNSFORD, III
  • ANTI-AMYLOID-BETA ANTIBODIES
    Publication number: 20180051072
    Abstract: The present invention relates, in part, to isolated antibodies that specifically interact with and show measurable binding affinity to an epitope of the amyloid-beta (A?) protein. Such antibodies may be used for the modulation of A? activity and/or aggregation or amyloidosis, to study the effects of the A? protein on cell function and, in certain embodiments, for the treatment and/or prevention of a disease or condition associated with A? activity, aggregation, and/or amyloidosis.
    Type: Application
    Filed: February 23, 2016
    Publication date: February 22, 2018
    Applicant: rPeptide LLC
    Inventors: Quentin FLORENCE, Nanda MENON, William MOFFITT, Bill LUNSFORD, III